The data were, however, not compatible with a protective intention-to-treat effect. They concluded: Randomized trials using MALO as an outcome might be unfeasible, motivating further large observational studies using appropriate methodology to further delineate the effect of GLP1 agonists on the risk of MALO, complementing future phase 3 trials of GLP1 agonists.
Obesity: A disease in and of itself
Semaglutide is unusual: it's on-patent, commercially available, and still legally compoundable due to shortage status
Phentermine and Caffeine: The Basics Phentermine is a central nervous system stimulant medication prescribed as a temporary weight loss aid, PubChem says
Patients in Louisiana and Texas who would like to lose weight but do not suffer from diabetes, cancer, heart, liver or kidney problems, and do not have a family history of medullary thyroid cancer (MTC) or multiple endocrine neoplasia type 2 (MEN2)